Nothing Special   »   [go: up one dir, main page]

Tate et al., 2023 - Google Patents

Peptidomimetic oligomers targeting membrane phosphatidylserine exhibit broad antiviral activity

Tate et al., 2023

View HTML
Document ID
7744143733805527930
Author
Tate P
Mastrodomenico V
Cunha C
McClure J
Barron A
Diamond G
Mounce B
Kirshenbaum K
Publication year
Publication venue
ACS Infectious Diseases

External Links

Snippet

The development of durable new antiviral therapies is challenging, as viruses can evolve rapidly to establish resistance and attenuate therapeutic efficacy. New compounds that selectively target conserved viral features are attractive therapeutic candidates, particularly …
Continue reading at pubs.acs.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Similar Documents

Publication Publication Date Title
Nathan et al. Calcium ions directly interact with the Ebola virus fusion peptide to promote structure–function changes that enhance infection
Meher et al. Membrane cholesterol modulates oligomeric status and peptide-membrane interaction of severe acute respiratory syndrome coronavirus fusion peptide
Guo et al. Interferon-induced transmembrane protein 3 blocks fusion of diverse enveloped viruses by altering mechanical properties of cell membranes
Luo Influenza virus entry
Chazal et al. Virus entry, assembly, budding, and membrane rafts
Hendricks et al. Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus
Ashhurst et al. Potent anti-SARS-CoV-2 activity by the natural product gallinamide A and analogues via inhibition of cathepsin L
Tate et al. Peptidomimetic oligomers targeting membrane phosphatidylserine exhibit broad antiviral activity
Soni et al. The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylserine-enriched membranes
Yang et al. An engineered arginine-rich α-helical antimicrobial peptide exhibits broad-spectrum bactericidal activity against pathogenic bacteria and reduces bacterial infections in mice
Prochnow et al. Labyrinthopeptins exert broad-spectrum antiviral activity through lipid-binding-mediated virolysis
Kors et al. VAP proteins–from organelle tethers to pathogenic host interactors and their role in neuronal disease
Park et al. Comparing the membrane-interaction profiles of two antiviral peptides: Insights into structure–function relationship
Jackman et al. Deciphering how pore formation causes strain-induced membrane lysis of lipid vesicles
Hyun et al. Proline hinged amphipathic α-helical peptide sensitizes gram-negative bacteria to various gram-positive antibiotics
Means et al. Balancing life and death: BCL‐2 family members at diverse ER–mitochondrial contact sites
Koufos et al. Use of a cholesterol recognition amino acid consensus peptide to inhibit binding of a bacterial toxin to cholesterol
Pattnaik et al. Enhanced cholesterol-dependent hemifusion by internal fusion peptide 1 of SARS coronavirus-2 compared to its N-terminal counterpart
Wu et al. Indole facilitates antimicrobial uptake in bacteria
Tamemoto et al. Rational design principles of attenuated cationic lytic peptides for intracellular delivery of biomacromolecules
Luteijn et al. A broad-spectrum antiviral peptide blocks infection of viruses by binding to phosphatidylserine in the viral envelope
Song et al. Design of an acid-activated antimicrobial peptide for tumor therapy
Krueger et al. Receptor-based peptides for inhibition of leukotoxin activity
Cesar-Silva et al. The endolysosomal system: The acid test for SARS-CoV-2
Nemésio et al. Membrane interacting regions of Dengue virus NS2A protein